Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

ACTO'S CXZONE WINS DUAL HONORS IN THE 2025 PHARMACEUTICAL TECHNOLOGY EXCELLENCE AWARDS
  • USA - English


News provided by

ACTO Technologies, Inc.

Dec 09, 2025, 08:30 ET

Share this article

Share toX

Share this article

Share toX

ACTO’S CxZone Wins Dual Honors In 2025 PHARMACEUTICAL TECHNOLOGY Excellence Awards -- The First and Only AI-Simulated Roleplay Solution Exclusively Designed for Pharmaceutical Field Professionals, CxZone was awarded for AI Roleplay and Field Simulation Excellence. (CNW Group/ACTO Technologies, Inc.)
ACTO’S CxZone Wins Dual Honors In 2025 PHARMACEUTICAL TECHNOLOGY Excellence Awards -- The First and Only AI-Simulated Roleplay Solution Exclusively Designed for Pharmaceutical Field Professionals, CxZone was awarded for AI Roleplay and Field Simulation Excellence. (CNW Group/ACTO Technologies, Inc.)
ACTO’S CxZone Wins Dual Honors In 2025 PHARMACEUTICAL TECHNOLOGY Excellence Awards (CNW Group/ACTO Technologies, Inc.)
ACTO’S CxZone Wins Dual Honors In 2025 PHARMACEUTICAL TECHNOLOGY Excellence Awards (CNW Group/ACTO Technologies, Inc.)

First and Only AI-Simulated Roleplay Solution Exclusively Designed for Pharmaceutical Field Professionals, Awarded for AI Roleplay and Field Simulation Excellence

TORONTO and NEW YORK, Dec. 9, 2025 /PRNewswire/ - ACTO, a leader in AI-first field excellence solutions for life sciences and a Veeva Product Partner and member of the Veeva AI Partner Program, today announced that ACTO's CxZone won dual honors in the 2025 Pharmaceutical Technology Excellence Awards.

As the first and only AI-simulated roleplay solution exclusively designed for pharmaceutical field professionals, CxZone won recognition in both the Innovation (AI Roleplay) and Product Launches (Field Simulation) categories. Read about ACTO's recognition in the 2025 Pharmaceutical Technology Excellence Awards here.

"This recognition validates our purpose-built approach to develop CxZone, which was to empower field reps to show up in the most human way possible," said Parth Khanna, CEO of ACTO. "CxZone can help field professionals rehearse difficult conversations, test different approaches, and build confidence. By helping field professionals speak the language of medicine with clarity and confidence, interactions with healthcare providers can be authentic in the moment and build more trust."

"The judges were impressed by how CxZone applies AI to a very real and complex industry challenge: turning strategy into meaningful, compliant conversations with healthcare professionals," said Tina Ross, Awards Manager at Pharmaceutical Technology. "By combining empathetic, clinically grounded simulations with seamless integration of current MLR‑approved content, ACTO stood out as a forward‑thinking partner to the life sciences sector and a clear winner across both Innovation and Product Launches categories."

Innovation (AI Roleplay) Award Category

In the category of Innovation (AI Roleplay), ACTO addressed persistent challenges in pharmaceutical field engagement. A significant hurdle facing pharmaceutical companies is ensuring that strategies developed at headquarters translate effectively into field conversations with healthcare providers (HCPs). According to industry data, only 28% of HCPs feel their interactions with field representatives meet their needs, despite substantial investments made in field forces. ACTO developed CxZone to improve field rep/HCP engagement and interactions.

Another recognized innovation was CxZone's integration with Veeva Vault PromoMats and MedComms, which allows practice scenarios to be built around the most current, medical, legal and regulatory (MLR)-approved content, an industry first.

Product Launches (Field Simulation) Award Category

In the second category, ACTO went beyond basic sales skill development to focus on what matters most in HCP conversations—allowing field teams to work on clinical fluency and product messaging, along with receiving specific "Clinical IQ" and "Messaging" scores and feedback. CxZone is built on ACTO's proprietary Empathetic AI engine, making the AI-simulated HCP interaction realistic and personal.

Traditional roleplay exercises can be uncomfortable and artificial for both participants and facilitators. Such "roleplay fatigue" can undermine and limit training effectiveness, especially when field teams must master complex clinical and product information in a short period. ACTO developed CxZone's gamified, on-demand environment to provide field professionals the ability to practice and simulate "real-life" clinical conversations without the pressure of live observation.

CxZone's backend user interface is also intuitive and easy, so trainers can design the HCP avatar, define the conversation, set evaluation criteria, and deploy the simulation to the field themselves in a matter of minutes. Practice scenarios in CxZone can be built around content auto-synced with Veeva PromoMats and MedComms, ensuring field professionals always practice with current, approved materials for their simulations to enhance the HCP experience.

As the first and only AI-simulated roleplay solution exclusively designed for life sciences field professionals, CxZone provides field reps and Medical Science Liaisons (MSLs) a judgment-free, on-demand practice environment with instant personalized feedback aligned to a company's unique sales process and coaching models.

For more information, visit www.acto.com/CxZone.

Visit www.acto.com, or follow ACTO on LinkedIn for the latest announcements and news.

About the Pharmaceutical Technology Excellence Awards

The Pharmaceutical Technology Excellence Awards is an independent recognition programme powered by the business intelligence of GlobalData. Its team of researchers and journalists, along with Artificial Intelligence, analyze over 1 billion datasets during the year to recognize, endorse and rank top-tier companies and their achievements in 200+ counties. One of the largest and widely recognized programs industrywide, its objective is to recognise forward-thinking, innovative companies that drive positive change in the industry. The program focuses on Areas of Excellence in business expansion, diversity, environmental, financing, innovation, investments, M&A, marketing, product launches, research and development, and safety and social.

About ACTO

ACTO is an Intelligent Field Excellence (IFE) platform built for life sciences that unifies human intelligence with empathetic AI to help Sales, Medical, Market Access, and Marketing teams improve customer engagement and brand performance. With ACTO, biopharma companies can ensure field professionals are always competent, confident, and credible in face-to-face HCP interactions, while providing senior leaders and frontline managers with the insight they need to drive continuous field force effectiveness. As a validated platform compliant with FDA 21 CFR Part 11 and SOC 2 Type II certified, ACTO is the trusted partner for intelligent field excellence in the life sciences industry.

SOURCE ACTO Technologies, Inc.

21%

more press release views with 
Request a Demo

Modal title

Also from this source

ACTO'S CXZONE WINS DUAL HONORS IN THE 2025 PHARMACEUTICAL TECHNOLOGY EXCELLENCE AWARDS

ACTO'S CXZONE WINS DUAL HONORS IN THE 2025 PHARMACEUTICAL TECHNOLOGY EXCELLENCE AWARDS

ACTO, a leader in AI-first field excellence solutions for life sciences and a Veeva Product Partner and member of the Veeva AI Partner Program, today ...

ACTO STELLT ACTOVERSE VOR: EIN MARKTPLATZ FÜR PARTNERLÖSUNGEN ZUR FÖRDERUNG VON INNOVATION UND EFFIZIENZ IM BEREICH EXZELLENZ AUF DEM VEEVA COMMERCIAL SUMMIT EUROPE

ACTO STELLT ACTOVERSE VOR: EIN MARKTPLATZ FÜR PARTNERLÖSUNGEN ZUR FÖRDERUNG VON INNOVATION UND EFFIZIENZ IM BEREICH EXZELLENZ AUF DEM VEEVA COMMERCIAL SUMMIT EUROPE

ACTO, ein führender Anbieter von KI-gestützten Spitzenlösungen für die Biowissenschaften, Veeva-Produktpartner und Mitglied des Veeva...

More Releases From This Source

Explore

STEM (Science, Tech, Engineering, Math)

STEM (Science, Tech, Engineering, Math)

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

Computer & Electronics

Computer & Electronics

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.